Me, Too
- PMID: 28717688
- PMCID: PMC5495449
- DOI: 10.1200/JGO.2015.000588
Me, Too
Conflict of interest statement
Author’s disclosures of potential conflicts of interest and author contributions are found at the end of this article.The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc. Bishal GyawaliNo relationship to disclose
References
-
- Walker J: High prices for drugs attacked at meeting. http://www.wsj.com/articles/high-prices-for-drugs-attacked-at-meeting-14....
-
- DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ. 2003;22:151–185. - PubMed
-
- Kantarjian H, Steensma D, Rius Sanjuan J, et al. High cancer drug prices in the United States: Reasons and proposed solutions. J Oncol Pract. 2014;10:e208–e211. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources